Literature DB >> 8302574

Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.

N Carlesso1, J D Griffin, B J Druker.   

Abstract

The Philadelphia chromosome, detected in virtually all cases of chronic myelogenous leukemia, is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR encoded sequences upstream of exon 2 of c-ABL. This oncogene produces a fusion protein, p210BCR-ABL, in which the ABL tyrosine kinase activity is elevated. This elevated kinase activity is essential for transformation, but the mechanisms involved are unknown. To investigate p210BCR-ABL function we constructed a model system in which the tyrosine kinase activity of p210BCR-ABL was inducible. Two amino acid substitutions, Arg to His at amino acid 457 and Tyr to His at amino acid 469 of c-abl, modeled on mutations known to render v-src temperature-sensitive for tyrosine kinase activity, were introduced into p210BCR-ABL. This mutant was characterized in an IL-3 growth factor dependent murine myeloid cell line, 32Dc13. Cell lines expressing the temperature-sensitive mutant remained factor dependent at the non-permissive temperature, but at the permissive temperature displayed a marked reduction in cell death in the absence of growth factor and an exaggerated proliferative response to low levels of IL-3. Both the kinase activity of the mutant and the levels of tyrosine phosphorylated proteins are increased in the temperature-sensitive mutant at the permissive temperature. Further, tyrosine phosphorylation of potential substrates of the p210BCR-ABL tyrosine kinase, p120 rasGAP and its associated proteins of p190 and p62, only occurs at the permissive temperature in cells expressing the temperature-sensitive mutant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302574

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.

Authors:  K Okuda; A D'Andrea; R A Etten; J D Griffin
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.

Authors:  G Bazzoni; N Carlesso; J D Griffin; M E Hemler
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

4.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.

Authors:  D Cortez; L Kadlec; A M Pendergast
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

5.  A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.

Authors:  J Y Reuther; G W Reuther; D Cortez; A M Pendergast; A S Baldwin
Journal:  Genes Dev       Date:  1998-04-01       Impact factor: 11.361

Review 6.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

7.  The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.

Authors:  Keiko Okuda; Yuko Sato; Yoshiaki Sonoda; James D Griffin
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

8.  Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.

Authors:  I Sánchez-García; G Grütz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

9.  Role of STAT3 in Transformation and Drug Resistance in CML.

Authors:  Rajesh R Nair; Joel H Tolentino; Lori A Hazlehurst
Journal:  Front Oncol       Date:  2012-04-10       Impact factor: 6.244

10.  Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL.

Authors:  T Matsuguchi; R C Inhorn; N Carlesso; G Xu; B Druker; J D Griffin
Journal:  EMBO J       Date:  1995-01-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.